Adjusted EPS increased 23% to $6.16 for the nine-month period.
Cost of educational services grew 13.2% in the quarter, outpacing revenue growth.
Refinanced Term Loan B to a new $510 million facility extending maturity to 2033.
Authorized a new $750 million share repurchase program with significant remaining capacity.
The latest 10-Q paints a picture of a company in a high-stakes race between operational scaling and financial fragility. On one hand, Covista is successfully growing its student base and expanding its revenue footprint, particularly within Walden and its medical schools. The successful extension of debt maturities provides a necessary breathing room that was previously lacking, suggesting that the immediate risk of a liquidity crisis has been mitigated. However, the trade-off is a balance sheet that remains stretched and a cost base that is creeping upward. The tension between aggressive share repurchases and the need for capital expenditures to support growth creates a precarious balancing act. For investors, the central question is whether the growth in enrollment and pricing power can outpace the rising costs of delivery and the inherent risks of a highly regulated federal funding environment. The upcoming quarters will be critical in determining if Covista can convert its top-line momentum into durable, sustainable margin expansion.